Clinigen

Getting the right medicine to the right patient at the right time.

[Clinigen @Clinigen]

📢 Exciting news! 🎉Today, we unveiled a strengthened leadership team. A warm welcome to Jerome Charton as CEO, and Michael Mensa as CFO. #Clinigen #Leadership #PharmaServices

https://t.co/j4fvKgLHiG

[Clinigen @Clinigen]

With an ambition to achieve net zero emissions by 2040 and a significant reduction as early as 2030, Clinigen is proud to announce its commitment to the Science Based Targets initiative (SBTi).

@ScienceTargets #ScienceBasedTargets #SBTiCommitment #ClimateResponsibility

[Clinigen @Clinigen]

@AngadSinghChha1 Hi Angad, thanks for getting in touch. We have sent you a private message to follow up with you on your enquiry.

Kind regards,
Sam (Clinigen Social Media Team)

[Clinigen @Clinigen]

We are proud to sponsor an all expert session on the current issues in the optimisation of Asparaginase use in clinical practice at @SIOPEurope, Tuesday 9th May 2023.

Register now to join us in Valencia.
https://t.co/fn8Q4pHPjr

[Clinigen @Clinigen]

Clinigen Insights 2023 – We are live!

Should Early Access be considered an integral part of a market access strategy?

Today and tomorrow, we’ll discuss this key topic and more at our Clinigen Insights event in Basel, Switzerland.

#earlyaccess #managedaccess #expandedaccess

[Clinigen @Clinigen]

We’re pleased to announce that Clinigen has entered into an agreement to divest Lamda Laboratories to Adragos Pharma.

Read the press release in full:
https://t.co/GDoDXxupm2

[Clinigen @Clinigen]

Final call for our free-to-attend 'Clinigen Insights Conference' with keynote speaker Tim Spector, Professor at King’s College London and co-founder of Zoe Ltd. 

Have a look at the full event agenda and register to attend: https://t.co/m24LrY4k06

[Clinigen @Clinigen]

Managed Access as part of a commercial strategy -

Join our free-of-charge Clinigen Insights event to learn what needs to be considered:

https://t.co/m24LrY4k06

Guest speakers include Shirle Zajac, Teva, Winston Smit, BristolMyersSquibb, Chris Hoyle & Joubert Gama, Immunocore.

[Clinigen @Clinigen]

This #InternationalWomensDay2023 we're celebrating the incredible women at Clinigen.

With 60% of our global workforce, and 60% of our Clinigen Management Academy graduates, identifying as female, we're immensely proud to provide an inclusive environment where women can thrive.

[Clinigen @Clinigen]

What are the recent changes in trends for #earlyaccess, and how can the updated regulatory framework in countries like France impact your #managedaccess strategy?

Join us at our Clinigen Insights conference next month to learn more: https://t.co/m24LrY4k06

[Clinigen @Clinigen]

New @DiversityRare & @RareDiseases survey aims to uncover gaps & barriers experienced by underrepresented communities.

Together, we can identify and combat longstanding barriers experienced by the #RareDisease community!

Participate and pass on: https://t.co/AKpX7YDSz9

[Clinigen @Clinigen]

There are over 300 million people, across the globe, living with rare diseases. That’s 5% of the worldwide population.

We are supporting the day by showing our colours and highlighting the great work #rarediseaseday does in helping those across the world. 

#rarediseaseday2023

[Clinigen @Clinigen]

We're delighted to have @timspector,  Professor at King’s College London and co-founder of Zoe Ltd., as keynote speaker at our Clinigen Insight conference in Basel next month: https://t.co/ipiwc9MGhq

Learn more about our event and register to join: https://t.co/m24LrY4k06

[Clinigen @Clinigen]

Together with guest speaker @mark_sheehan_ox, Associate Professor at the University of Oxford, we'll discuss how #patientengagement and ethical considerations can be integrated into the planning of a MAP.

Join our Clinigen Insights conference next month: https://t.co/m24LrY4k06

[Clinigen @Clinigen]

Clinigen Insights: Together with Florence Barkats, Chief Commercial Officer at CISIV, we will present examples of real-world data collection and how #RealWorldEvidence can add value to market access.

Join our Clinigen Insights event to learn more: https://t.co/m24LrY4k06

[Clinigen @Clinigen]

Clinigen is delighted to announce it has entered into an agreement to divest Proleukin® to Iovance Biotherapeutics for £166.7 million.

The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties.

Find out more:
https://t.co/Jrw337nbkP

[Clinigen @Clinigen]

Clinigen is excited to announce they have entered into an agreement with Accord Healthcare to initiate a Managed Access Program in Europe for relugolix (ORGOVYX®).

#managedaccess #earlyaccess

[Clinigen @Clinigen]

Join us next year as we will be hosting our Clinigen Insights conference in Basel, Switzerland, on 23-24 March 2023, following BIO-Europe Spring 2023.

Discover more and RSVP: https://t.co/B3Yg7nrZii

#managedaccess #expandedaccess

[Clinigen @Clinigen]

Clinigen welcomes the results of the MIROCALS study and is proud of the part one of our medicines played in this important research.

[Clinigen @Clinigen]

Clinigen are excited to announce the acquisition of Drug Safety Navigator, a specialist Pharmacovigilance service provider based in the US.

Read the press release in full:
https://t.co/Eghchh1he2

#healthcare #clinigen #pharmacovigilance